Vivani Medical, Inc.
VANIW
Other OTC0.01
USD
-0.01
- -
CIK
0001266806
ISIN
US92854B1171
Return %
Stock
S&P500
1Y
-92.63
26.53
3Y
-99.47
76.60
5Y
-99.45
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Adam Mendelsohn
- Full Time Employees
- 50
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 5858 Horton Street EmeryVille CA United States of America 94608
- CIK
- 0001266806
- Website
- vivani.com
- Similar Companies
- Business
- Vivani Medical, Inc. (NASDAQ: VANIW) is a clinical-stage biopharmaceutical company that develops miniaturized, long-term, subdermal drug implants utilizing proprietary NanoPortal technology to deliver steady medication levels for chronic conditions including obesity and type 2 diabetes; core pipeline assets include NPM-139, a semaglutide implant for chronic weight management with once- or twice-yearly dosing potential, NPM-115, a six-month exenatide implant for obesity, NPM-119 and NPM-133, lower-dose exenatide and semaglutide implants for type 2 diabetes, and exploratory programs in cardiometabolic and veterinary applications. The company, founded in 2003 and headquartered in Alameda, California, operates primarily in the United States with preclinical and early clinical activities focused on GLP-1 therapies to address medication non-adherence and tolerability issues. Recent developments include positive preclinical weight loss data and Phase 1 LIBERATE-1 results for NPM-115 in 2025, prioritization and accelerated advancement of NPM-139 toward Phase 1 trials in the first half of 2026, expansion of a collaboration with Okava Pharmaceuticals in April 2025 to develop OKV-119 for weight management and diabetes in dogs and cats, $10 million equity financing in August 2025 followed by $15.7 million registered direct offering in October 2025 and additional closings, announcement of a planned spin-off of its Cortigent Neuromodulation subsidiary in September 2025 with subsequent withdrawal of the record date in October 2025, and ongoing business updates through Q3 2025 financial results.